Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review

Frontiers in Public Health

Public Health

Cate Dewey¹  Lia Reynolds¹  Ghaid Asfour¹  Matthew Little² 

[1] Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada;Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada;School of Public Health and Social Policy, Faculty of Human and Social Development, University of Victoria, Victoria, BC, Canada;

关键词: SARS-CoV-2;    COVID-19;    vaccine efficacy;    systematic review;    mRNA vaccines;    AstraZeneca vaccine;   

DOI  :  10.3389/fpubh.2023.1229716

 received in 2023-05-26, accepted in 2023-09-15,  发布年份 2023

来源: Frontiers

【 摘 要 】

The purpose of this systematic review was to report on the vaccine efficacy (VE) of three SARS-CoV-2 vaccines approved by Health Canada: Pfizer BioNTech, Moderna, and AstraZeneca. Four databases were searched for primary publications on population-level VE. Ninety-two publications matched the inclusion criteria, and the extracted data were separated by vaccine type: mRNA vaccines (Pfizer and Moderna) and the AstraZeneca vaccine. The median VE for PCR-positive patients and various levels of clinical disease was determined for the first and second doses of both vaccine types against multiple SARS-CoV-2 variants. The median VE for PCR-positive infections against unidentified variants from an mRNA vaccine was 64.5 and 89%, respectively, after one or two doses. The median VE for PCR-positive infections against unidentified variants from the AstraZeneca vaccine was 53.4 and 69.6%, respectively, after one or two doses. The median VE for two doses of mRNA for asymptomatic, symptomatic, and severe infection against unidentified variants was 85.5, 93.2, and 92.2%, respectively. The median VE for two doses of AstraZeneca for asymptomatic, symptomatic, and severe infection against unidentified variants was 69.7, 71, and 90.2%, respectively. Vaccine efficacy numerically increased from the first to the second dose, increased from the first 2 weeks to the second 2 weeks post-vaccination for both doses, but decreased after 4 months from the second dose. Vaccine efficacy did not differ by person's age.

【 授权许可】

Unknown   
Copyright © 2023 Reynolds, Dewey, Asfour and Little.